P1129: ACALABRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): RESULTS OF A PHASE 2, MULTICENTER, OPEN-LABEL TRIAL

• P. Strati,
• M. Coleman,
• D. Stevens,
• S. Ma,
• C. Patti,
• M. Levy,
• I. S. Lossos,
• P. Ramakrishnan Geethakumari,
• S. Lam,
• R. Calvo,
• K. Higgins,
• L. Budde

Affiliations

P. Strati

1 The University of Texas MD Anderson Cancer Center, Houston, TX

M. Coleman

2 Clinical Research Alliance/Weill Cornell Medicine, New York City, NY

D. Stevens

3 Norton Cancer Institute, Louisville, KY

S. Ma

4 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America

C. Patti

5 A.O.O.R. Villa Sofia-Cervello, U. O. Ematologia I, Palermo, Italy

M. Levy

6 Baylor University Medical Center, Dallas, TX

I. S. Lossos

7 Sylvester Comprehensive Cancer Center, University of Miami−Miller School of Medicine, Miami, FL

P. Ramakrishnan Geethakumari

8 Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Cente, Dallas, TX, United States of America

S. Lam

9 London Health Sciences Centre, London, Ontario, Canada

R. Calvo

10 AstraZeneca, Gaithersburg, MD

K. Higgins

11 AstraZeneca, South San Francisco, CA

L. Budde

12 City Of Hope National Medical Center, Duarte, CA, United States of America